Headlines about Cerecor (NASDAQ:CERC) have trended somewhat positive on Wednesday, according to Accern. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cerecor earned a news impact score of 0.16 on Accern’s scale. Accern also gave news articles about the company an impact score of 47.012785840129 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Shares of Cerecor (NASDAQ CERC) traded down 2.65% on Wednesday, hitting $1.10. The stock had a trading volume of 26,036 shares. The firm has a 50 day moving average of $0.94 and a 200 day moving average of $0.72. The stock’s market cap is $28.66 million. Cerecor has a 12 month low of $0.34 and a 12 month high of $5.60.
Cerecor (NASDAQ:CERC) last posted its earnings results on Monday, August 14th. The company reported ($0.14) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.29) by $0.15. Cerecor had a negative return on equity of 1,325.84% and a negative net margin of 1,106.99%. The company had revenue of $0.16 million for the quarter. On average, equities analysts forecast that Cerecor will post ($1.07) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This report was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.com-unik.info/2017/11/01/cerecor-cerc-getting-somewhat-favorable-press-coverage-study-finds.html.
In other Cerecor news, major shareholder Armistice Capital Master Fund bought 39,479 shares of Cerecor stock in a transaction that occurred on Friday, September 1st. The shares were purchased at an average cost of $0.76 per share, for a total transaction of $30,004.04. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders bought 1,638,693 shares of company stock worth $1,053,475 over the last 90 days. Company insiders own 10.70% of the company’s stock.
Cerecor, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.
What are top analysts saying about Cerecor Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cerecor Inc. and related companies.